Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017093301) 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/093301 International Application No.: PCT/EP2016/079253
Publication Date: 08.06.2017 International Filing Date: 30.11.2016
IPC:
C07D 417/14 (2006.01) ,A61K 31/433 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433
Thiadiazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
ASTRAZENECA AB [SE/SE]; 151 85 Södertälje, SE
CANCER RESEARCH TECHNOLOGY LIMITED [GB/GB]; Angel Building 407 St John Street London EC1V 4AD, GB
Inventors:
FINLAY, Maurice, Raymond, Verschoyle; GB
PERKINS, David, Robert; GB
NISSINK, Johannes, Wilhelmus, Maria; GB
RAUBO, Piotr, Antoni; GB
SMITH, Peter, Duncan; GB
BAILEY, Andrew; GB
Agent:
COOK, Andrew; GB
Priority Data:
62/26078430.11.2015US
Title (EN) 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER
(FR) COMPOSÉS DE 1,3,4-THIADIAZOLE ET LEUR UTILISATION POUR TRAITER LE CANCER
Abstract:
(EN) A compound of Formula (I) or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6- fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are -(CH2)3; or R1 and R2 taken together can be -(CH2)2- and R3 can be -CH3; R4 halo, -CH3, -OCH3, -OCHF2, -OCF3, or -CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
(FR) L'invention concerne un composé de formule (I) ou son sel pharmaceutiquement acceptable. Dans la formule, Q peut être pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 peut être H; R2 et R3 peuvent être chacun indépendamment alkyle en C1-C6, ou R2 et R3 forment ensemble -(CH2)3; ou R1 et R2 peuvent former ensemble -(CH2)2- et R3 peut être -CH3; R4 halo, -CH3, -OCH3, -OCHF2, -OCF3, ou -CN; et n peut être 0, 1 ou 2. Le composé de formule (I) peut inhiber une glutaminase, par exemple GLS1.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AO3664CA3005517AU2016361834SG11201803808VDOP2018000135IN201817012358
MYPI 2018702070IL259508KR1020180083411CN108349965EP3383872ID2018/10664
BR112018008330EA201891239PH1/2018/501133